

IPX203
IR CD-LD
Levodopa Mean (ng/mL)
3000
2500
2000
1500
1000
500
0
0
1
2
3
4
5
6
7
8
Time (hr)

FIG. 1



IPX203
IR CD-LD
Levodopa Mean (ng/mL)
1500
1200
900
600
300
0
0
1
2
3
4
5
6
7
8
Time (hr)
Note: Values are normalized to 100 mg LD for IR CD-LD and 280 mg LD for IPX203.

FIG. 2



IPX203
IR CD-LD
Carbidopa Mean (ng/mL)
500
400
300
200
100
0
0
1
2
3
4
5
6
7
8
Time (hr)

FIG. 3



IPX203
IR CD-LD
Levodopa Mean (ng/mL)
3000
2500
2000
1500
1000
500
0
0
1
2
3
4
5
6
7
8
9
10
Time (hr)

FIG. 4




IPX203
IR CD-LD
Carbidopa Mean (ng/mL)
500
400
300
200
100
0
0
1
2
3
4
5
6
7
8
9
10
Time (hr)

FIG. 5



Note: Day 1 post-rescue values were imputed to the predose value. Asterisks indicate the time points at which a statistically significant treatment difference was noted.

FIG. 6



Mean LD Concentration (ng/mL)
4000
3500
3000
2500
2000
1500
1000
500
0
0
1
2
3
4
5
6
7
8
Time (hr)
Abbreviation: Cp = plasma concentration
Mean Change from Baseline MDS-UPDRS-III
5
0
-5
-10
-15
-20
-25
-30
IPX203 Mean Cp
IR Mean Cp
IPX203 MDS-UPDRS-III
IR CD-LD MDS-UPDRS-III

FIG. 7



Mean LD Concentration (ng/mL)
4000
3500
3000
2500
2000
1500
1000
500
0
0
1
2
3
4
5
6
7
8
9
10
Time (hr)
Abbreviation: Cp = plasma concentration
Mean Change from Baseline MDS-UPDRS-III
5
0
-5
-10
-15
-20
-25
-30
-35
IPX203 Mean Cp
IR Mean Cp
IPX203 MDS-UPDRS-III
IR CD-LD MDS-UPDRS-III

FIG. 8



IPX203
IR CD-LD
Rytary
Levodopa Mean (ng/mL)
2500
2000
1500
1000
500
0
0
1
2
3
4
5
6
7
8
9
10
Time (hr)

FIG. 9



IPX203
IR CD-LD
Rytary
Carbidopa Mean (ng/mL)
500
400
300
200
100
0
0
1
2
3
4
5
6
7
8
9
10
Time (hr)

FIG. 10



Motor State - Completers (N=25)
Hours
0
1
2
3
4
5
6
7
8
9
p=0.023
p<0.0001
p<0.0001
p=0.0002
p=0.0079
p=0.009
p=0.0259
p<0.0001
p<0.0001
OFF Time
ON Time Without Dyskinesia
ON Time With Nontroublesome Dyskinesia
ON Time With Troublesome Dyskinesia
Good ON Time
IPX203 (N=25) 4.52 3 2.3 0.15 5.31
IR (N=25) 7.23 1.3 1.44 0.03 2.74
Rytary (N=25) 5.41 2.46 2 0.14 4.45

FIG. 11



IPX203 (N=25)
IR (N=25)
Rytary (N=25)
Δ MDS-UPDRS Part III
5
0
-5
-10
-15
-20
-25
-30
0
2
4
6
8
10
Hours
Horizontal dashed lines represent 4-, 7-, and 13-point improvements from average predose value.

FIG. 12



Hours of Improvement in MDS-UPDRS III
Hours
0
1
2
3
4
5
6
7
p=0.0290
p<0.0001
p=0.0003
p=0.0005
p<0.0001
p=0.0041
p-0.0134
p<0.0001
p=0.0049
4-Point
7-Point
13-Point
6.01
5.72
4.72
3.66
3.16
2.17
5.15
4.31
3.53
IPX203 (N=25)
IR (N=25)
Rytary (N=25)

FIG. 13



Mean LD Concentration (ng/mL)
4000
3500
3000
2500
2000
1500
1000
500
0
0
1
2
3
4
5
6
7
8
9
10
Time (h)
Cp = plasma concentration
Mean Change from Baseline MDS-UPDRS-III
5
0
-5
-10
-15
-20
-25
-30
IPX203 Mean Cp
IR Mean Cp
Rytary Mean Cp
IPX203 MDS-UPDRS-III
IR CD-LD MDS-UPDRS-III
Rytary MDS-UPDRS-III

FIG. 14



Formulation = A
Formulation = E
Mean_Concentration (ng/mL)
600
400
200
0
0
5
10
15
20
25
Time (hr)
Analyte = Levodopa

FIG. 15



Formulation = A
Formulation = E
Mean_Concentration (ng/mL)
150
100
50
0
0
5
10
15
20
25
Time (hr)
Analyte = Carbidopa

FIG. 16



IPX-203
IR CD-LD
Mean "Good On" Time (Hours)
12.5
12
11.5
11
10.5
10
9.5
9
Enrollment
Randomization
Baseline
IR CD/LD
Dose Adjustment
IPX-203
Dose Conversion
IPX-203 or IR CD/LD
Double Blind Treatment on Stable / Optimized Dose
V1
Week
0
V2
Week
3
V4
Week
7
V5
Week
10
V6
Week
15
V7/EOS
Week
20
9.61
9.46
10.28
10.23
11.72
11.67
11.15
11.04
11.35
11.35
10.85
10.77

FIG. 17



4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
3.76
2.21
1.55*
*P<0.0001
IPX203
N = 249
IR CD-LD
N = 246
Difference IPX203-IR

FIG. 18



IPX-203
IR CD-LD
Mean "OFF" Time (Hours)
6.5
6
5.5
5
4.5
4
3.5
3
Enrollment
Randomization
Baseline
IR CD/LD Dose Adjustment
IPX-203 Dose Conversion
IPX-203 or IR CD/LD Double Blind Treatment on Stable / Optimized Dose
6.15
6.05
5.46
5.41
4.02
3.95
4.68
4.32
4.83
4.21
4.75
4.18
V1 Week 0
V2 Week 3
V4 Week 7
V5 Week 10
V6 Week 15
V7/EOS Week 20

FIG. 19



Sprinkled
Fed
Fasted
Mean_Concentration (ng/mL)
2000
1500
1000
500
0
0
5
10
15
20
25
Time (hr)

FIG. 20



Sprinkled
Fed
Fasted
Mean_Concentration (ng/mL)
0
100
200
300
400
0
5
10
15
20
25
Time (hr)

FIG. 21